Results 41 to 50 of about 1,457,629 (200)

Baseline Neuroinflammation Stratifies TSPO‐PET Response to Disease‐Modifying Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate which baseline clinical and imaging characteristics best predict TSPO‐PET‐measurable reduction in glial activation following treatment of multiple sclerosis (MS), to utilize this information for designing more efficient biomarker‐based clinical trials targeting glial activation.
Marlene T. Morch   +5 more
wiley   +1 more source

Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia

open access: yes, 2017
Ibrutinib is a bruton tyrosine kinase (BTK) inhibitor approved for B cell malignancies. Although there are currently two clinical trials evaluating ibrutinib in combination with nivolumab (programmed cell death protein 1, PD-1, inhibitor) or everolimus ...
Gregory W. Hosier, Naji J. Touma
core   +1 more source

Evolution of breast cancer therapeutics: Breast tumour kinase’s role in breast cancer and hope for breast tumour kinase targeted therapy [PDF]

open access: yes, 2014
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). © 2014 Baishideng Publishing Group Inc.There have been significant improvements in the detection
Hussain, HA, Harvey, A
core   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

PENAPISAN VIRTUAL BERBASIS STRUKTUR DARI DATABASE BAHAN ALAM ZINC SEBAGAI INHIBITOR BRUTON TYROSINE KINASE

open access: yesJIIS: Jurnal Ilmiah Ibnu Sina, 2019
ABSTRAK   Bruton Tirosin kinase (BTK) memainkan peran penting dalam banyak jalur pensinyalan seluler sehingga menjadikannya target potensial dalam mengobati penyakit autoimun dan kanker.
Fauzan Zein Muttaqin   +4 more
doaj   +3 more sources

Single‐Cell Transcriptomic Profiling Identifies B Cell‐Intrinsic Dysregulation of Sphingolipid Biosynthesis and Could Be Improved by Inhibiting UGCG in Primary Immune Thrombocytopenia

open access: yesAdvanced Science, EarlyView.
This study generates the single‐cell atlas of pathogenic B‐cell subset Bc‐5 in ITP. It identifies RUNX3 as a key survival regulator and uncovers sphingolipid‐driven metabolic reprogramming, validating UGCG inhibition as a therapeutic candidate and building a valuable resource for ITP mechanistic and therapeutic exploration.
Dongmei Luo   +10 more
wiley   +1 more source

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac   +16 more
wiley   +1 more source

Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib, a highly selective, non‐covalent Bruton tyrosine kinase inhibitor (BTKi) previously demonstrated durable efficacy and tolerable safety following covalent (c) BTKi therapy in heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Michael L. Wang   +36 more
wiley   +1 more source

Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report

open access: yesCase Reports in Oncology, 2021
Primary CNS lymphoma (PCNSL) is a highly aggressive malignant disease with a high recurrence rate and a poor prognosis. We present the case of a 71-year-old woman diagnosed with PCNSL in June 2010.
Anna Mair   +5 more
doaj   +1 more source

The synergistic impact of granulocytic myeloid‐derived suppressor cells and innate lymphoid cells in systemic sclerosis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid‐derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc‐associated fibrosis and their interactions with other immune cell populations remain poorly ...
Stefanie Weber   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy